Archive

CNBC Says That IRA Negotiations Will Be 'Intense.' Here's Why They Won't

CNBC Says That IRA Negotiations Will Be 'Intense.' Here's Why They Won't

And CMS will pilot a new way for Medicaid to pay for gene therapy

Brian Reid
Brian Reid
How to Think About the Size of the Price Controls that CMS May Impose

How to Think About the Size of the Price Controls that CMS May Impose

And a must-read piece about why the cost-effectiveness analyses of the future will show drugs are a great deal

Brian Reid
Brian Reid
Bernie Will Get CEOs to Capitol Hill; NC Will Not Get Obesity Meds to Its Beneficiaries

Bernie Will Get CEOs to Capitol Hill; NC Will Not Get Obesity Meds to Its Beneficiaries

And other reasons why the next 10 days in DrugPricingLand are going to be so intense

Brian Reid
Brian Reid
NEJM Study Adds to Overwhelming Evidence on Hospital Markups ... and the Need for 340B Reform

NEJM Study Adds to Overwhelming Evidence on Hospital Markups ... and the Need for 340B Reform

Plus: am I naive for being amazed that Optum is making loans to health care providers?

Brian Reid
Brian Reid
Tyson Foods Ditches Their Mega-PBM In Favor of an Upstart 'To Really Get a Partner'

Tyson Foods Ditches Their Mega-PBM In Favor of an Upstart 'To Really Get a Partner'

And I'm still stuck on the Arnold Ventures net-price denialism

Brian Reid
Brian Reid
BioCentury Goes Deep on How Arnold Ventures Shaped the IRA ... and Where It's Going Next

BioCentury Goes Deep on How Arnold Ventures Shaped the IRA ... and Where It's Going Next

Plus a must-read letter to the CBO from No Patient Left Behind

Brian Reid
Brian Reid
Looking at Which 2022 Drug Approvals Received the Most Attention Around Pricing

Looking at Which 2022 Drug Approvals Received the Most Attention Around Pricing

Plus some musings on why news-you-can-use around drug pricing is so often shallow

Brian Reid
Brian Reid
The Reaction to a New Piece About Price Hikes Shows Why We Can't Have Nice Things

The Reaction to a New Piece About Price Hikes Shows Why We Can't Have Nice Things

And Mark Cuban convinces me (mostly) that maybe transparency alone could fix the drug-price debate

Brian Reid
Brian Reid
The NYT's Off-the-Mark Explainer Is Making Smart Conversations on Drug Pricing Harder

The NYT's Off-the-Mark Explainer Is Making Smart Conversations on Drug Pricing Harder

Plus news on 340B, biosimilars, prior auth and more

Brian Reid
Brian Reid
The Breast Cancer Death Rate Is Way, Way Down. There's a Lesson In That.

The Breast Cancer Death Rate Is Way, Way Down. There's a Lesson In That.

Plus a good, if dispiriting, look at the state of access to a breakthrough postpartum depression pill

Brian Reid
Brian Reid
UnitedHealth Group Made $5.5 Billion Last Quarter, Even Though (or Maybe Because) Insurance Keeps Getting Worse

UnitedHealth Group Made $5.5 Billion Last Quarter, Even Though (or Maybe Because) Insurance Keeps Getting Worse

And a lot of Arnold Ventures-adjacent items, too

Brian Reid
Brian Reid
Valuing Obesity Drugs Isn't 'Clever' Or 'Depressing,' and Other #JPM24 Thoughts

Valuing Obesity Drugs Isn't 'Clever' Or 'Depressing,' and Other #JPM24 Thoughts

Plus more thinking on importation, 340B, and international pricing

Brian Reid
Brian Reid
FirstBack
1314151617181920
Next Last